PharmaTech Integrates 2023 Track 3
MANUFACTURE AND FORMULATION
Focusing on advances in manufacturing, formulation and drug delivery technologies
Welcome and Fireside Chat 1
Welcome and Opening Remarks
Dave Tudor | Managing Director | Medicines Manufacturing Innovation Centre, CPI
Fireside Chat 1: Future Industry Challenges
– What are the future challenges facing the Pharma industry?
– What role will Digital Innovation play?
Ian McCubbin | Chair | RoslinCT | Chair | Cell and Gene Therapy Catapult
Ian Rees | Regulatory Affairs Consultant | DI REES Ltd
David Littlejohn | Special Advisor to the Principal | University of Strathclyde
Maureen Wedderburn | Non Executive Chair, Medicines Manufacturing Innovation Centre | CPI
Session 2: This is intense
The industry has a well established batch-based supply chain, often based around multipurpose plant. These offer product flexibility, and scale-up from development into manufacturing is well understood. However, scale-up often compromises the optimum process conditions, resulting in less resource efficient processes and increased cost. The “make to stock” business model these facilities dictate can adversely impact response to changes in demand. As governments seek to build resilience in the medicines supply chain post pandemic, and the industry seeks to reach net zero, the time may have come for more widespread uptake of process intensification. This panel will explore the strengths, weaknesses, opportunities and threats of these technologies.
Mark Talford | Deputy Challenge Director – Medicines Manufacturing Challenge | Innovate UK
Jon-Paul Sherlock | Head of Innovative Manufacturing Technology | AstraZeneca
Gareth Jenkins | Vice President, Science and Technology | Quotient Sciences
Dai Hayward MBE | Chief Executive Officer | Micropore
Chris Van Der Walle | Edinburgh Centre Director | Cell & Gene Therapy Catapult
Rolf Hemminga | Vice President Global Sales & Marketing Life Sciences | Emerson
Session 3: Manufacturing as a key to achieving Net Zero
Many companies have signed up to Net Zero. With a significant proportion of emissions associated with the design of medicines and processes – what does manufacturing need to deliver to achieve net zero and how can Manufacturing Technologies deliver a Sustainability future?
Unfortunately there is not a recording available for this session.
John Arthur | Director, Medicines Manufacturing Innovation Centre | CPI
Cait Murray-Green | Chief Executive Officer | Strategic Scientific Consulting
Andy Brittan | Head of Technology Development & Digitalisation | Booth Welsh
Ray Black | Interim CEO | Net Zero Nation
Manish Gupta | Lead Decarbonization Architect | Atos
Session 4: Uncertainty is certain!
Managing manufacturing and supply chains for unpredictable demand. What’s the reality in delivering agility?
Andy Dwyer | Senior VP of CMC and Supply Chain | Summit Therapeutics
Nicholas Wigdahl | Established Product Strategy Group Lead | Roche Pharma Technical Services
Janet Fernihough | Director, R&D Consulting | Syneos Health
Iain Bomphray | Director of the Lightweight Manufacturing Centre | National Manufacturing Institute Scotland
Jim McGuire | Grand Challenge Lead | Medicines Manufacturing Innovation Centre, CPI
Fireside Chat 2 and Closing Remarks
Fireside Chat 2: Transforming Drug Development
– Exploring Breakthrough Digital Technologies and System Thinking Approaches to Revolutionise Manufacturing and Supply
Rebecca Vangenechten | Head Vertical Pharma Segment | Siemens
Chris Kopinski | Head of Strategy & Business Development HCLS/Manufacturing Industry Products | Amazon Web Services (AWS)
Paul Hardy | Client Executive Partner | Atos
Dave Tudor | Managing Director, Medicines Manufacturing Innovation Centre, Biologics & Quality | CPI